Now RAC is well on track to obtain PRV (Priority Review Voucher) from FDA with this path: 1. RPD (Rare Paediatric Disease) Designation 2. IND submission to prepare Phase 2/3 Trials, which would be funded by potential partners RAC has engaged in discussions with through an agreement with Biosynergy Partners. 3. PRV could be awarded by FDA once IND is approved. This voucher alone is worth US$110-130 million (approx. A$150-175 million). Once awarded, a PRV can be sold to another pharmaceutical company for use with another drug and indication. 4. RAC intends to sell PRV. POTENTIAL IS HUGE!
2019 SP, page-44
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $282.0M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
